GHRP-6 vs GHRH

GHRP-6 (growth hormone-releasing peptide-6) and GHRH (growth hormone-releasing hormone) are the two fundamental hypothalamic signals that control growth hormone (GH) secretion from the anterior pituitary. GHRH provides the primary stimulatory drive; ghrelin (which GHRP-6 mimics) provides the secondary, augmenting signal. Understanding their distinct signaling pathways is essential for rational GH secretagogue therapy.

Molecular Profiles

GHRH

GHRH is a 44-amino acid neuropeptide produced by the arcuate nucleus:

• Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-NH₂
• Molecular weight: ~5,040 Da
• Receptor: GHRH receptor (GHRHR) — Gs-coupled
• Signaling: Gs → adenylyl cyclase → cAMP → PKA → GH gene transcription
• Source: Arcuate nucleus → median eminence → hypophyseal portal system

GHRP-6

GHRP-6 is a synthetic hexapeptide ghrelin receptor agonist:

• Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
• Molecular weight: ~873 Da
• Receptor: GHSR1a (ghrelin receptor) — Gq-coupled
• Signaling: Gq → PLC → IP₃/DAG → Ca²⁺ → GH exocytosis
• Source: Synthetic (mimics endogenous ghrelin)

Hypothalamic-Pituitary GH Axis

The GH axis involves two complementary hypothalamic inputs:

GHRH Pathway (Primary Stimulus)

1. Arcuate nucleus neurons produce GHRH in response to metabolic signals (hypoglycemia, amino acids, exercise, sleep onset).
2. GHRH release into the hypophyseal portal system via median eminence.
3. GHRHR activation on somatotrophs → Gs → cAMP → PKA.
4. GH gene transcription: PKA phosphorylates CREB → GH gene promoter activation → GH mRNA synthesis.
5. GH exocytosis: Sustained cAMP elevation triggers GH vesicle fusion and release.

GHRH provides the pulse amplitude — determining how much GH is released per pulse. GHRH also drives somatotroph proliferation and GH gene expression.

Ghrelin/GHS Pathway (Secondary Augmentation)

1. Gastric oxyntic cells produce ghrelin (the endogenous ligand for GHSR1a) in response to fasting.
2. Ghrelin circulates to the anterior pituitary and hypothalamus.
3. GHSR1a activation on somatotrophs → Gq → PLC → IP₃ → Ca²⁺ release.
4. GH exocytosis: Ca²⁺ influx triggers immediate GH vesicle release from pre-formed stores.
5. Hypothalamic effect: Ghrelin also activates GHRH neurons in the arcuate nucleus, indirectly augmenting GHRH release.

The ghrelin pathway provides the pulse frequency — determining how often GH pulses occur. GHRP-6 mimics this pathway.

Signaling Comparison

Property	GHRH	GHRP-6
Receptor	GHRHR (Gs)	GHSR1a (Gq)
Second messenger	cAMP	IP₃/DAG/Ca²⁺
GH effect	Synthesis + release	Release only
Pulsatility	Drives pulse amplitude	Drives pulse frequency
Onset	Slow (gene transcription)	Fast (Ca²⁺-dependent)
Duration	Hours	Minutes
Somatotroph growth	Promotes	Minimal
Hypothalamic effect	Direct (arcuate)	Indirect (via GHRH neurons)

Synergistic Mechanism

When both pathways are activated simultaneously:

1. Complementary signaling: GHRH (cAMP) and ghrelin (Ca²⁺) activate parallel second messenger systems in the same somatotroph.
2. Enhanced GH release: The combined signal produces greater GH release than either alone — typically 2–4× greater.
3. Sustained response: GHRH provides prolonged GH synthesis; ghrelin provides rapid release — together they produce sustained GH elevation.
4. IGF-1 amplification: Greater GH release produces greater hepatic IGF-1 secretion.

This synergy is the pharmacological basis for combining GH secretagogues (e.g., CJC-1295 + ipamorelin, GHRP-6 + GHRH).

Clinical Evidence

GHRH

• Sermorelin: Synthetic GHRH(1-29) — FDA-approved for GH deficiency diagnosis, withdrawn from market.
• Tesamorelin: Modified GHRH — FDA-approved for HIV-associated lipodystrophy.
• CJC-1295: GHRH analogue with DAC — investigational for GH deficiency and anti-aging.
• GH stimulation test: GHRH-arginine test is a validated diagnostic tool for GH deficiency.

GHRP-6

• GH stimulation: GHRP-6 produces robust GH release (5–10× baseline) in healthy volunteers and GH-deficient patients.
• Appetite stimulation: GHRP-6 is a potent orexigenic agent — clinically relevant for cachexia and wasting.
• Acute GH deficiency: GHRP-6 can acutely correct GH deficiency in critically ill patients.
• Research tool: GHRP-6 is widely used in research to probe ghrelin receptor function.

Comparative Effects

Effect	GHRH	GHRP-6
GH release magnitude	Moderate (3–5× baseline)	Strong (5–10× baseline)
Onset of GH release	15–30 min	5–10 min
Duration of GH elevation	3–4 hours	1–2 hours
IGF-1 elevation	Moderate	Moderate
Appetite stimulation	Minimal	Very strong
Cortisol elevation	Minimal	Significant (30–50%)
Prolactin elevation	Minimal	Significant (50–100%)
Somatotroph growth	Promotes	Minimal
Oral bioavailability	No	No

Clinical Positioning

Consideration	GHRH	GHRP-6
Primary role	GH synthesis + release	GH release + appetite
Best for GH deficiency	Yes (physiological)	Yes (acute correction)
Best for cachexia	No	Yes (appetite stimulation)
Best for chronic therapy	Yes (pulse amplitude)	Less suitable (side effects)
Side effect burden	Low	High (cortisol, prolactin)
Clinical evidence	Moderate (tesamorelin)	Limited (research tool)

Summary

GHRH and GHRP-6 represent the two fundamental hypothalamic controls of GH secretion — GHRH providing pulse amplitude through cAMP-mediated gene transcription, and ghrelin/GHRP-6 providing pulse frequency through Ca²⁺-dependent exocytosis. Their complementary mechanisms produce synergistic GH release when combined, forming the pharmacological basis for dual secretagogue therapy. GHRH analogues (tesamorelin, CJC-1295) offer more physiological GH stimulation with fewer off-target effects, while GHRP-6 provides rapid, potent GH release with significant appetite stimulation — useful in specific clinical contexts (cachexia, acute GH deficiency) but limited by cortisol and prolactin elevation for chronic therapy.